Oxinium Pharmaceuticals Private Limited
About Oxinium Pharmaceuticals Private Limited
Data last updated:
Oxinium Pharmaceuticals Private Limited is a private limited company based in Jaysingpur, Maharashtra, India. It operates in the pharmaceutical retail and distribution segment of the pharmaceuticals sector. It was incorporated on 14 July 2014 and has been in existence for over 12 years.
The company is registered with the Registrar of Companies (ROC), Pune, under CIN U74999PN2014PTC151815. Its GSTIN is 27AACCO0249A1ZZ (Maharashtra).
The company has an authorised share capital of ₹10 Lakh and a paid-up capital of ₹3 Lakh. It is led by directors Anjali Satishkumar Patil and Satishkumar Adgonda Patil.
Its last annual general meeting (AGM) was held on 30 November 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Patil Institute Ortho Sciences Sa Nr S T Stand Tal – Shirol Jaysingpur, Maharashtra, India – 416101.
As per the financials filed for FY 2024, the company reported a revenue of ₹4.36 Cr, a growth of 35% compared to the previous year. For the same year it recorded a net profit of ₹2.8 Lakh (net margin 0.6%) and EBITDA of ₹4.58 Lakh (EBITDA margin 1.1%). Revenue has grown at a compounded annual rate (CAGR) of 1% over three years and 13% over five years.
The current compliance status is marked as compliant by the Registrar of Companies.
Company details
Contact details
Oxinium Pharmaceuticals Private Limited's registered office is in Jaysingpur, Maharashtra. Its e-mail address is in the company report.
- Email
- Registered AddressPatil Institute Ortho Sciences Sa Nr S T Stand Tal – Shirol Jaysingpur, Maharashtra, India – 416101
- IndustryPharma, Pharmaceutical Retailers & Distributors
To see the full contact details of Oxinium Pharmaceuticals Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Oxinium Pharmaceuticals is trade. In detail, this covers wholesale trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Oxinium Pharmaceuticals Private Limited, buy the company report.
Financials of Oxinium Pharmaceuticals Private Limited
FY 2025 filings availableOxinium Pharmaceuticals Private Limited reported revenue of ₹4.36 Cr (up 35% YoY) for FY 2024.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 13% over five years, including 35% growth in the latest year. EBITDA rose 96% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹4.58 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹2.8 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 1.1% | ||||
| Net Profit Margin | 0.6% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Oxinium Pharmaceuticals Private Limited, buy the company report.
Board of directors of Oxinium Pharmaceuticals Private Limited
Oxinium Pharmaceuticals has 2 current directors and 1 former director. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Anjali Satishkumar Patil Also directs: Pios Medilinks Private Limited, Nekszen Academy Foundation | Director | 14 Jul 2014 | 12 Years 3 Months | Current |
| Satishkumar Adgonda Patil | Director | 14 Jul 2014 | 12 Years 3 Months | Current |
Peer comparison
Oxinium Pharmaceuticals Private Limited is compared with the 6 companies closest to it by revenue in the Pharma industry (Pharma Retail and Distribution, Pharmaceuticals), with the same principal business activity (wholesale trading), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Carewise Health Ventures Private Limited | ₹4.38 Cr (FY 2024) | 24.0% | Ernakulam, Kerala, India | |||
| Poorvanchal Lifecare Private Limited | ₹4.38 Cr (FY 2024) | 8292.0% | Kolkata, West Bengal, India | |||
| Quin Chem Private Ltd | ₹4.37 Cr (FY 2023) | -21.0% | Chennai, Tamil Nadu, India | |||
| Oxinium Pharmaceuticals Private Limitedthis company | ₹4.36 Cr (FY 2024) | ₹2.8 Lakh | 0.6% | 35.0% | Jaysingpur, Maharashtra, India | |
| Bluebug Life Science Private Limited | ₹4.36 Cr (FY 2025) | 31.0% | Gurgaon, Haryana, India | |||
| Meltic Healthcare Private Limited | ₹4.34 Cr (FY 2025) | 13.0% | Shahabad Markanda, Haryana, India | |||
| Anexas Pharmaceuticals Private Limited | ₹4.34 Cr (FY 2025) | -8.0% | Agra, Uttar Pradesh, India |
To see the full peer comparison of Oxinium Pharmaceuticals Private Limited, buy the company report.
Auditor
Oxinium Pharmaceuticals Private Limited is audited by LIMAYE & CO for the financial year 2018.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| LIMAYE & CO | FY 2018 | 105614W |
Shareholding
The shareholding of Oxinium Pharmaceuticals Private Limited is on record for 4 financial years, the latest being FY 2018, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|
| Promoters | ||||
| Domestic institutional investors (DII) | ||||
| Foreign institutional investors (FII) | ||||
| Public | ||||
| Others |
To see the full shareholding pattern of Oxinium Pharmaceuticals Private Limited, buy the company report.
Legal cases
No court or tribunal cases involving Oxinium Pharmaceuticals Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Oxinium Pharmaceuticals Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Oxinium Pharmaceuticals has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AACCO0249A1ZZ | Maharashtra | Active | 23 Aug 2017 |
To see the full GST registrations and return filing status of Oxinium Pharmaceuticals Private Limited, buy the company report.
Recent activity
Oxinium Pharmaceuticals Private Limited has 3 board changes on record since 2014: 2 appointments and 1 cessation. The latest: Sharad Adgonda Patil ceased to be Director on 11 May 2015.
Frequently asked questions
Oxinium Pharmaceuticals is an active private limited company based in Jaysingpur, Maharashtra, India. The company works in pharmaceutical retailers and distributors, within the pharma industry. It was incorporated on 14 July 2014 (12+ years old) and is registered under CIN U74999PN2014PTC151815.
Oxinium Pharmaceuticals has 2 current directors:
- Anjali Satishkumar Patil - Director
- Satishkumar Adgonda Patil - Director
The latest financial statements of Oxinium Pharmaceuticals on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 November 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Oxinium Pharmaceuticals is 27AACCO0249A1ZZ, registered in Maharashtra.
The CIN (Corporate Identification Number) of Oxinium Pharmaceuticals is U74999PN2014PTC151815. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Oxinium Pharmaceuticals was incorporated on 14 July 2014, making it 12+ years old. It is registered with the Registrar of Companies, Pune.
The peers of Oxinium Pharmaceuticals by revenue are Carewise Health Ventures Private Limited, Poorvanchal Lifecare Private Limited, Quin Chem Private Ltd, Bluebug Life Science Private Limited, Meltic Healthcare Private Limited and 1 more, all in the Pharma industry (Pharma Retail and Distribution, Pharmaceuticals), with the same principal business activity (wholesale trading).
Sharad Adgonda Patil ceased to be Director on 11 May 2015. Anjali Satishkumar Patil was appointed as Director on 14 Jul 2014. Satishkumar Adgonda Patil was appointed as Director on 14 Jul 2014.
The registered office of Oxinium Pharmaceuticals is at Patil Institute Ortho Sciences Sa Nr S T Stand Tal – Shirol Jaysingpur, Maharashtra, India – 416101.
Oxinium Pharmaceuticals operates in the pharma industry, in the pharmaceutical retailers and distributors segment.
The compliance status of Oxinium Pharmaceuticals is compliant as of 11 August 2026. The company is actively filing with the Registrar of Companies.